Top 15 Drug Launch Superstars

FiercePharma | Tracy Staton

A year ago, FiercePharma published a list of drugs that missed when stepping on the up escalator. A heel got caught, or a sleeve. Bystanders hit the emergency stop button. For whatever reason, escalate they did not. We called it "Top 10 Drug Launch Disasters." It's still one of our most popular special reports.

This year, we wanted to take a more positive approach. So, herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience. Turns out, as tough as it may be to identify disasters before they happen, it's not so difficult after the fact. To go back to the escalator analogy, it's like trying to pick Will Ferrell out of an ascending crowd when he's wearing an elf costume and doing the splits.

How “Micro-Moves” Can Drive Major Health-Care Change

 

HBR Blog Network | Karen Golden-Biddle 

The complexity of today’s healthcare organizations makes it hard to change the way they do things. Conventional wisdom holds that real transformation requires bringing in consultants, undertaking large-scale and highly visible action, and jolting the organization into change. 

But there’s another, far less disruptive approach: what I call “micro-moves.” These are small and often barely visible actions and interactions that my research and that of others has found to generate real and consequential change, rather than derailing it as sweeping organizational makeovers often do. By inviting collaboration in the change process from people across the organization, micro-moves tap collective energy and build enthusiasm that is essential for driving change. 

10 αλλαγές συστήνει η επιτροπή για την ΠΦΥ

 

Γράφει ο Αιμίλιος Νεγκής 

Σε δέκα ουσιαστικά αλλαγές καταλήγει το πόρισμα της επιτροπής Σουλιώτη για την πρωτοβάθμια φροντίδα, το οποίο σήμερα κατατίθεται στον υπουργός Υγείας. 

Η Επιτροπή υπολογίζει ότι για την υποστήριξη ενός αποτελεσματικού συστήματος πρωτοβάθμιας φροντίδας υγείας απαιτείται μια μετατόπιση πόρων, έτσι ώστε οι σχετικές δαπάνες να μην υπολείπονται του 15% των δημοσίων δαπανών του συστήματος υγείας. Αυτό με τα σημερινά δεδομένα εκτιμάται ότι προσεγγίζει το 1,5 δισ. €. 

Η Επιτροπή υπογραμμίζει την ανάγκη επαναπροσδιορισμού των πόρων που διατίθενται για την ΠΦΥ στην Ελλάδα, καθώς, με τα σημερινά δεδομένα, φαίνεται πως οι ανάγκες των πολιτών έχουν υποεκτιμηθεί. Ειδικότερα, ανάμεσα στα άλλα, η επιτροπή καταλήγει στις ακόλουθες 10 προτάσεις: